M-type K+ channels in nociceptive pathways: physiological roles and therapeutic potential

Authors

Professor Nikita Gamper

Overview

Presentation from Metrion Biosciences’ external speaker series, Professor Nikita Gamper, University of Leeds, 5th February 2019.

Please contact us if you would like any further information regarding our suite of cardiac safety services.

Background

Professor Nikita Gamper, the ninth contributor to Metrion Biosciences External Speaker Series, gives a presentation on M-type K+ channels in nociceptive pathways: physiological roles and therapeutic potential from his ion channel research.

M type K channels in nociceptive pathways Slide 2 copy
M-type K+ channels in nociceptive pathways: physiological roles and therapeutic potential – Slide 2
M type K channels in nociceptive pathways Slide 4 copy
M-type K+ channels in nociceptive pathways: physiological roles and therapeutic potential – Slide 4

Extract from our Interview with Professor Nikita Gamper

You currently split your time between Leeds University and your role as Adjunct Professor of Pharmacology position at Hebei Medical University in China. What influenced you to collaborate with this team of scientists? 

There is quite a list of reasons actually. But most important are the following: i) robust, dynamic and enthusiastic research group at HebMU; ii) strong cohort of PhD and Masters students; iii) collegiate and friendly environment; iii) generous intramural and extramural funding; iv) booming biotech industry giving access to affordable cutting edge technologies.

Nikita gave the ninth presentation in Metrion Biosciences External Speaker Series in February 2019, his interview can be found in our ConnectIONS blog article here.

Download
Recommended Publications
Latest Publications
A clinically translatable hiPSC cardiomyocyte model to predict QTc and QRS cardiac risk

Presented at the SPS meeting in September 2024, Dr Steve Jenkinson presents Metrion’s human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay, an advanced tool, providing key advantages, for early cardiac derisking in drug discovery.

Validation of an impedance-based phenotypic screening assay able to detect multiple mechanisms of chronic cardiotoxicity in human stem cell-derived cardiomyocytes

Presentation by Marc Rogers, CSO Metrion Biosciences, Nanion technologies Exhibitor session, 2020 Biophysical Society meeting, San Diego USA.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram